Original ArticleVirosome-bound antigen enhances DC-dependent specific CD4+ T cell stimulation, inducing a Th1 and Treg profile in vitro
Graphical Abstract
Virosomes and liposomes are spherical unilamellar structures comprised of phosphilipids. Virosomes additionally contain fractions from the influenza virus envelope, hemagglutinin (HA) and neuraminidase (NA). To study the interaction of such nanocarriers with dendritic cells (DCs), we fluorescently labeled and coupled them with ovalbumin (OVA). Murine bone marrow-derived dendritic cells (BMDCs) were treated with virosomes or liposomes prior to determining OVA-specific CD4+ T cell proliferation in an in vitro co-culture of BMDCs and T cells. BMDCs treated with OVA-coupled virosomes induced enhanced antigen-specific CD4+ T cell proliferation compared to treatment with empty virosomes and soluble OVA protein or OVA-coupled liposomes.
Section snippets
Mice
8-12 week old female BALB/c and BALB/c DO11.10 T cell receptor transgenic mice were bred specific pathogen free at the Department of Clinical Research, University of Bern (Bern, Switzerland) in compliance with the Swiss Federal Veterinary Office guidelines under animal experimentation permission (BE71/15).
Cell cultures
BMDCs were derived from bone marrow of BALB/c mice as previously described.22 Briefly, BMDCs were allowed to differentiate for 8 days at 37 °C in a 5% CO2 humidified incubator in Iscove's Modified
Nanocarrier characterization
Both nanocarriers, virosomes and liposomes (Figure 1), were extensively characterized for size, homogeneity, zeta potential, HA, OVA, as well as endotoxin content. Size was measured by dynamic light scattering (DLS) and routinely resulted in a hydrodynamic diameter of approximately 100 nm (Table 1). Nanocarrier quality was uniform and reproducible throughout all experiments. Protein concentration of both OVA and HA was determined by performing SDS-PAGE, Spotblot and Western blot, and HA
Discussion
Influenza virosomes and liposomes are already being utilized in a broad range of clinical and therapeutic applications such as vaccinations10, 15, 29 or cancer therapy.30, 31, 32, 33, 34 To date insufficient information is available on the interaction and the fate of nanocarriers when taken up by APCs. With the current study we investigated how interaction of such bio-mimetic antigen carriers affect DC activation, function and T cell stimulatory capacity. We showed that both virosomes and
Acknowledgments
We gratefully acknowledge the expert technical assistance provided by Sandra Barnowski, Andrea Stokes and Dr. Amiq Gazdhar.
References (49)
- et al.
Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection
J Control Release
(2013) - et al.
A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses
Vaccine
(2007) - et al.
A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy
Biomaterials
(2013) - et al.
Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity
Vaccine
(2005) - et al.
Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial
Clin Immunol
(2008) - et al.
Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis a vaccine: a randomized controlled trial
Vaccine
(1996) Influenza immunization
Biologicals
(1997)- et al.
Inactivated virosome hepatitis a vaccine
Lancet
(1994) - et al.
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow
J Immunol Methods
(1999) Doxil® - the first FDA-approved nano-drug: lessons learned
Pegylated liposomal doxorubicin (Lipo-dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up
Gynecol Oncol
Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation
Vaccine
Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48 hours
Adv Healthc Mater
Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination
Sci Transl Med
Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells
Biomacromolecules
Fluorescence-encoded gold nanoparticles: library design and modulation of cellular uptake into dendritic cells
Small
The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles
Surface charge of polymer coated SPIONs influences the serum protein adsorption, colloidal stability and subsequent cell interaction in vitro
Nanoscale
Size-dependent accumulation of particles in lysosomes modulates dendritic cell function through impaired antigen degradation
Int J Nanomedicine
Influenza virosomes as a vaccine adjuvant and carrier system
Expert Rev Vaccines
Influenza virosomes as vaccine adjuvant and carrier system
Expert Rev Vaccines
Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells
Int Immunol
Epaxal: a virosomal vaccine to prevent hepatitis A infection
Expert Rev Vaccines
Immunobiology of dendritic cells
Annu Rev Immunol
Cited by (12)
Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment
2023, Asian Journal of Pharmaceutical SciencesBioinspired and biomimetic micro- and nanostructures in biomedicine
2022, Journal of Controlled ReleaseCitation Excerpt :These are virus-like particles, and they are similar to the native virus only in terms of morphology and characteristics of cell entry. They have a reconstituted viral envelop without the genetic material of the original virus [129]. Virosome can be used as a vehicle for tumor-targeted drug delivery.
Silk Fibroin-Coated Nano-MOFs Enhance the Thermal Stability and Immunogenicity of HBsAg
2024, ACS Applied Materials and InterfacesCD96 Downregulation Promotes the Immune Response of CD4 T Cells and Associates with Ankylosing Spondylitis
2022, BioMed Research InternationalImmunization of hens
2021, IgY-Technology: Production and Application of Egg Yolk Antibodies: Basic Knowledge for a Successful Practice
Financial and competing interest disclosure: This study was funded by the Swiss National Science Foundation SNF 146249. The authors have no other affiliations or financial involvement with any organization or entity with a financial interest.
Funding: Flow Cytometry experiments were performed with the support of the FACSLab at the University of Bern, Switzerland. Microscopy acquisition and analysis were performed with the support of the Microscopy Imaging Center at the University of Bern, Switzerland. This study was supported by the Swiss National Science Foundation SNF grants 146249 and 316030_145003.
- 1
Contributed equally to this work as senior authors.